Theranos’ second lab director bought $5K a month to rubber-stamp kinds


Enlarge / Elizabeth Holmes, founder and former CEO of blood-testing and life sciences firm Theranos, leaves the courthouse along with her husband, Billy Evans, after the primary day of her fraud trial in San Jose, California, on September 8, 2021.

In yesterday’s installment of the Elizabeth Holmes felony trial, the jury heard some eye-opening testimony from Sunil Dhawan, the physician Theranos employed to interchange its earlier lab director.
Dhawan was the longtime dermatologist of Theranos COO Ramesh “Sunny” Balwani, who might be going through the identical fraud prices as Holmes within the spring. Dhawan was a board-certified physician, so he met state and federal necessities to be a lab director.
However not like Adam Rosendorff, the earlier director who resigned over the questionable accuracy of the corporate’s check outcomes, Dhawan was not board licensed in laboratory science, nor did he have any prior expertise operating a lab of that scale or scope. Dhawan additionally admitted that he needed to google Theranos’ tech when Balwani initially approached him—earlier than he was recruited, he hadn’t recognized a lot concerning the firm’s expertise.
However after some googling and “one brief dialog about it,” Dhawan agreed to function Theranos’ lab director as long as it didn’t intervene along with his day job as a dermatologist or his household life. “The time dedication could be very minimal,” Balwani assured him.
And it was. Dhawan testified that he went to Theranos twice and that he labored a complete of 5 to 10 hours between November 2014 and June 2015. In that point, he principally signed no matter Balwani despatched him. Theranos agreed to pay him $5,000 per 30 days, although he says he by no means cashed any checks and as soon as requested to be paid in inventory choices as an alternative.
State inspection
Issues ramped up a bit in September 2015, when he needed to go to Theranos’ headquarters to signal 300 normal working procedures in individual. “Rosendorff’s signature offered consolation to me—gave me some reassurance there had been some supervision earlier than my arrival,” Dhawan mentioned. Additionally in September 2015, Dhawan was current for a state inspection of the lab.
Earlier than the lab inspection, Dhawan hadn’t spoken with anybody who labored within the lab. “There wasn’t one time you spoke to a Theranos worker who labored within the lab?” assistant US legal professional Jeff Schenk requested him.

“I don’t recall any dialog in that size of time,” Dhawan mentioned. He additionally mentioned he didn’t meet with another workers, docs, or sufferers. He didn’t meet Holmes till September 2015.
After the lab inspection, Dhawan mentioned the work dwindled, and nobody at Theranos instructed him when he was relieved from his put up.
Beneath cross-examination by Holmes’ legal professional Lance Wade, Dhawan mentioned that he assumed Balwani was “a prime government.” 
“He was operating the laboratory from an operational standpoint, right?” Wade requested.
“I can’t touch upon that as a result of I used to be by no means instructed he was operating the lab,” Dhawan mentioned, “however it was my assumption he was, yeah.”
Extra particulars on Walgreens deal
Earlier than Dhawan’s testimony started, the jury heard from Nimesh Jhaveri, a former Walgreens government, who described the prospect of a finger-prick blood check as “extraordinary.” Veinous attracts require phlebotomists. “Much less blood required was the precise magic, it was so intriguing to us at Walgreens,” he mentioned.
His firm introduced in September 2013 that it had invested $140 million in Theranos, however already in early 2014, issues have been rising. Theranos was nonetheless drawing veinous blood round 40 p.c of the time, far greater than Jhaveri wished. In the end, he wished to drive the share to zero, he mentioned. Balwani instructed him that they’d get under 5 p.c by the tip of the yr, a goal Theranos by no means reached.
Walgreens had rolled out the startup’s expertise in 40 drugstores in Arizona and one in California, however Theranos’ testing wasn’t residing as much as its promise. “We have to have a documented detailed plan on each or it will likely be tough for me to persuade growth past AZ,” Jhaveri wrote to Balwani. Walgreens had plans to increase it to 500 shops in fiscal yr 2015, a goal they scaled again to 200.
“Value was an impediment, coaching our crew members was an impediment, hiring phlebotomists was an impediment,” Jhaveri instructed the court docket. “Your entire working mannequin was not perfected, in order that’s why we determined to scale back the quantity.” In the end, Walgreens by no means expanded past the preliminary rollout of 40 shops in Arizona and one retailer in California.
Holmes’ legal professional Kevin Downey tried to distance his shopper from the matter in cross-examination, asking Jhaveri what number of instances he met with Holmes. “Perhaps two or 3 times at most,” he replied.
Jhaveri instructed the prosecution that when information articles started to interrupt in 2015 about Theranos, its expertise, and its funds, the connection between the 2 firms started to unravel slowly at first, then shortly. In January 2016, Walgreens stopped providing Theranos’ checks at one retailer, and by June, they have been all “turned off,” Jhaveri mentioned. In November, Walgreens sued the startup for $125 million.